Has Gregory Redish received payments from drug or device companies?

Yes. Drug and device makers reported $3,120 in general payments to Gregory Redish across 119 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Gregory Redish did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Gregory Redish come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Gregory Redish

Cardiovascular Disease · Dallas, TXNPI 1194710970

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.4% of the total across 119 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Abbott at 40.3% of the total. Reporting peaked in 2019 at $1,559 and has fallen 97.4% since, to $41 in 2024. That places this record below the midpoint for cardiovascular disease clinicians in TX, where the typical reported total is $3,258.

$3,120in general payments, 2019–2025

Across 119 payments — averaging $26.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Abbott$1K
Boston Scientific$387
Amarin Pharma, Inc.$356
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$292
AstraZeneca$248
E.r. Squibb & Sons, L.L.C.$107
plus $473 from 10 others

What the payments were for

Food & beverage$3,10399%
Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Abbott	23	$1,257
Boston Scientific	7	$387
Amarin Pharma, Inc.	21	$356
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	17	$292
AstraZeneca	15	$248
E.r. Squibb & Sons, L.L.C.	7	$107
Novartis	7	$104
Johnson & Johnson	6	$104
Amgen	4	$70
Pfizer	3	$51
Alnylam Pharmaceuticals Inc.	2	$40
Kowa Pharmaceuticals America, Inc.	2	$27
Sanofi-aventis U.S. LLC	2	$27
Siemens Medical Solutions USA, Inc.	1	$20
Bardy Diagnostics, Inc.	1	$16
Chiesi USA, Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Confirm Rx$244
RESONATE$216

How this compares

$3,120 in reported general payments places this provider in the 45th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas →

Other cardiovascular disease in Dallas

Ramin Farzaneh-FarDallas$17.1M
Darren McGuireDallas$1.2M
Peter McCulloughDallas$664K
Ann NavarDallas$616K
Milton PackerDallas$530K
Amarinder BindraDallas$512K
Ambarish PandeyDallas$325K
Eric PetersonDallas$187K
Brittany WeberDallas$186K
James de LemosDallas$181K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →